Reported 12 months ago
Among blue-chip giants, penny stocks offer potential for high returns but come with high volatility risks. Analysts at Piper Sandler recommend two penny stocks that could see a 300% increase in value, Zura Bio and Monte Rosa Therapeutics. Zura Bio focuses on immunology drugs with a projected upside of 659%, while Monte Rosa uses protein degradation for treatment approaches with a forecasted 315% gain. Both stocks have a 'Strong Buy' consensus rating and positive outlook from other analysts.
Source: YAHOO